The AHA and ASA have replaced their 2016 stroke rehabilitation guideline with expanded, evidence-graded recommendations helping clinicians decide on care settings, comorbidity management, and long-term recovery support.

A randomized clinical trial found that intravenous tirofiban plus aspirin did not significantly reduce early neurological deterioration or new stroke compared with aspirin alone i patients with branch atheromatous disease–related stroke.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 4, 2026.

Amy Waldman, MD, Medical Director of the Leukodystrophy Center at Children's Hospital of Philadelphia, discusses zilganersen's mechanism, safety profile, clinical considerations, and what the first-ever approval for Alexander disease means for the broader leukodystrophy field.

Results recently published from the phase 2 HIMALAYA trial reported that SAR443820 did not slow functional decline, and was associated with more adverse events and treatment discontinuations in patients with ALS.

Alit Stark-Inbar, PhD, Chief Scientific Officer of Theranica, writes about migraine prevention beyond lifestyle changes, highlighting the role of neuromodulation and other evidence-based treatments in long-term management.

A new study reported that tremor and myoclonus affected nearly 7 in 10 patients with chronic inflammatory demyelinating polyneuropathy, with immunotherapy and beta-blockers showing potential benefit for symptom improvement.

Michela Leocadi, PhD, research fellow at UCL Queen Square Institute of Neurology, discussed new longitudinal data showing early functional connectivity changes in HD gene carriers years before clinical motor diagnosis.